Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bio-Techne Corp (TECH)

Bio-Techne Corp (TECH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,999,177
  • Shares Outstanding, K 156,453
  • Annual Sales, $ 1,220 M
  • Annual Income, $ 73,400 K
  • EBIT $ 117 M
  • EBITDA $ 227 M
  • 60-Month Beta 1.48
  • Price/Sales 7.47
  • Price/Cash Flow 23.83
  • Price/Book 4.53

Options Overview Details

View History
  • Implied Volatility 46.62% (-2.06%)
  • Historical Volatility 39.22%
  • IV Percentile 40%
  • IV Rank 35.36%
  • IV High 71.44% on 04/07/25
  • IV Low 33.04% on 02/21/25
  • Expected Move (DTE 26) 5.36 (9.31%)
  • Put/Call Vol Ratio 0.48
  • Today's Volume 108
  • Volume Avg (30-Day) 1,842
  • Put/Call OI Ratio 1.45
  • Today's Open Interest 21,032
  • Open Int (30-Day) 21,995
  • Expected Range 52.17 to 62.88

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 0.48
  • Number of Estimates 6
  • High Estimate 0.51
  • Low Estimate 0.40
  • Prior Year 0.50
  • Growth Rate Est. (year over year) -4.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
56.61 +1.61%
on 02/20/26
72.16 -20.29%
on 01/22/26
-12.05 (-17.31%)
since 01/20/26
3-Month
56.59 +1.64%
on 12/16/25
72.16 -20.29%
on 01/22/26
-1.21 (-2.06%)
since 11/20/25
52-Week
46.01 +25.02%
on 04/21/25
72.16 -20.29%
on 01/22/26
-7.97 (-12.17%)
since 02/20/25

Most Recent Stories

More News
1 Profitable Stock to Target This Week and 2 We Avoid

1 Profitable Stock to Target This Week and 2 We Avoid

TECH : 57.52 (-1.25%)
FAST : 46.22 (+0.02%)
ELV : 342.93 (-1.51%)
Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge‑Based Immunoassays for European Clinical Laboratories

MINNEAPOLIS  , Feb. 16, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced that the Ella benchtop...

TECH : 57.52 (-1.25%)
3 Profitable Stocks with Open Questions

3 Profitable Stocks with Open Questions

AAON : 102.30 (+1.27%)
TECH : 57.52 (-1.25%)
VLTO : 93.08 (-0.96%)
What Are Wall Street Analysts' Target Price for Bio-Techne Stock?

Although Bio-Techne has underperformed the broader market over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

TECH : 57.52 (-1.25%)
WFC : 88.70 (+1.29%)
$SPX : 6,909.51 (+0.69%)
IBB : 174.39 (-0.37%)
Bio-Techne Announces Changes to its Leadership Team

MINNEAPOLIS , Feb. 11, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, will be...

TECH : 57.52 (-1.25%)
5 Insightful Analyst Questions From Bio-Techne’s Q4 Earnings Call

5 Insightful Analyst Questions From Bio-Techne’s Q4 Earnings Call

TECH : 57.52 (-1.25%)
TECH Q4 Deep Dive: Margin Expansion and Flat Revenue Amid Mixed End Markets

TECH Q4 Deep Dive: Margin Expansion and Flat Revenue Amid Mixed End Markets

TECH : 57.52 (-1.25%)
Techne: Fiscal Q2 Earnings Snapshot

Techne: Fiscal Q2 Earnings Snapshot

TECH : 57.52 (-1.25%)
Bio-Techne (NASDAQ:TECH) Surprises With Q4 CY2025 Sales

Bio-Techne (NASDAQ:TECH) Surprises With Q4 CY2025 Sales

TECH : 57.52 (-1.25%)
Bio-Techne Releases Second Quarter Fiscal 2026 Results

MINNEAPOLIS , Feb. 4, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ending December 31, 2025.

TECH : 57.52 (-1.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Bio-Techne Corporation is a global life sciences company. It develops, manufactures, and sells biotechnology products and clinical diagnostic controls. It provides proteins, such as cytokines, growth factors, and enzymes; antibodies, including polyclonal and monoclonal antibodies; immunoassays comprising...

See More

Key Turning Points

3rd Resistance Point 60.20
2nd Resistance Point 59.30
1st Resistance Point 58.41
Last Price 57.52
1st Support Level 56.62
2nd Support Level 55.72
3rd Support Level 54.83

See More

52-Week High 72.16
Fibonacci 61.8% 62.17
Fibonacci 50% 59.08
Last Price 57.52
Fibonacci 38.2% 56.00
52-Week Low 46.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar